A Meta-Analysis of the Relationship between FGFR3 and TP53 Mutations in Bladder Cancer

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Neuzillet, Yann ^a,b,c   Paoletti, Xavier ^d   Ouerhani, Slah ^b,c,e,f,g   Mongiat Artus, Pierre ^h,i   Soliman, Hany ^h,i   de The, Hugues ^c,h   Sibony, Mathilde ^j   Denoux, Yves ^k   Molinie, Vincent ^l   Herault, Aurélie ^b,c   Lepage, May Linda ^b,c   Maille, Pascale ^m   Renou, Audrey ^m   Vordos, Dimitri ^m   Abbou, Claude Clément ^e,m   Bakkar, Ashraf ⁿ   Asselain, Bernard ^d   Kourda, Nadia ^o   El Gaaied, Amel ^f   Leroy, Karen ^m   Laplanche, Agnès ^p   Benhamou, Simone ^p   Lebret, Thierry ^a   Allory, Yves ^e,m   Radvanyi, François ^b,c   more..

^a LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^b INSTITUT CURIE   (France)

^c CNRS   (France)

^d INSERM U900   (France)

^e INSERM   (France)

^f FACULTÉ DES SCIENCES DE TUNIS   (Tunisia)

^g PASTEUR INSTITUTE OF TUNIS   (Tunisia)

^h SAINT LOUIS HOSPITAL   (France)

ⁱ Institut Universitaire d'Hématologie   (France)

^j HÔPITAL TENON   (France)

^k FOCH HOSPITAL   (France)

^l SAINT JOSEPH HOSPITAL   (France)

^m HENRI MONDOR HOSPITAL   (France)

ⁿ SINAI UNIVERSITY   (Egypt)

^o CHARLES NICOLLE HOSPITAL   (Tunisia)

^p INSTITUT GUSTAVE ROUSSY   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3; PROTEIN P53;

ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER GROWTH; CANCER STAGING; EXON; FGFR3 GENE; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; META ANALYSIS; SYSTEMATIC REVIEW; TP53 GENE; TUMOR GENE;

DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; MALE; MEDICAL ONCOLOGY; MUTATION; PREVALENCE; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 84871321456     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048993     Document Type: Article

References (34)

1. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
2. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, et al. (2010) AJCC Cancer Staging Manual. Springer-Verlag: New York, USA.
3. Spruck CH 3rd, Ohneseit PF, Gonzalez-Zulueta M, Esrig D, Miyao N, et al. (1994) Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 54: 784-788.
4. Billerey C, Chopin D, Aubriot-Lorton MH, Ricol D, Gil Diez de Medina S, et al. (2001) Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 158: 1955-1959.
5. Wu XR, (2005) Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 5: 713-725.
6. Knowles MA, (2007) Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target. World J Urol 25: 581-593.
7. Vallot C, Stransky N, Bernard-Pierrot I, Hérault A, Zucman-Rossi J, et al. (2011) A novel epigenetic phenotype associated with the most aggressive pathway of bladder tumor progression. J Natl Cancer Inst 103: 47-60.
8. Cappellen D, De Oliveira C, Ricol D, de Medina S, Bourdin J, et al. (1999) Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 23: 18-20.
9. Kimura T, Suzuki H, Ohashi T, Asano K, Kiyota H, et al. (2001) The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low-grade or superficial bladder carcinomas. Cancer 92: 2555-2561.
10. Bakkar AA, Wallerand H, Radvanyi F, Lahaye JB, Pissard S, et al. (2003) FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 63: 8108-8112.
11. van Rhijn BW, van Tilborg AA, Lurkin I, Bonaventure J, de Vries A, et al. (2002) Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders. Eur J Hum Genet 10: 819-824.
12. Hernández S, López-Knowles E, Lloreta J, Kogevinas M, Jaramillo R, et al. (2005) FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis. Clin Cancer Res 11: 5444-5450.
13. Zieger K, Dyrskjøt L, Wiuf C, Jensen JL, Andersen CL, et al. (2005) Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors. Clin Cancer Res 11: 7709-7719.
14. Lindgren D, Liedberg F, Andersson A, Chebil G, Gudjonsson S, et al. (2006) Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q. Oncogene 25: 2685-2696.
15. Lamy A, Gobet F, Laurent M, Blanchard F, Varin C, et al. (2006) Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations. J Urol 176: 2686-2689.
16. Ouerhani S, Rouissi K, Kourda N, Marrakchi R, Bougatef K, et al. (2009) Combined analysis of smoking, TP53 and FGFR3 mutations in Tunisian patients with invasive and superficial high grade bladder tumors. Cancer Invest 27: 998-1007.
17. Hartmann A, Schlake G, Zaak D, Hungerhuber E, Hofstetter A, et al. (2002) Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. Cancer Res 62: 809-818.
18. Jebar AH, Hurst CD, Tomlinson DC, Johnston C, Taylor CF, et al. (2005) FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 24: 5218-5225.
19. Simon R, Struckmann K, Schraml P, Wagner U, Forster T, et al. (2002) Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer. Oncogene 21: 2476-2483.
20. Gui Y, Guo G, Huang Y, Hu X, Tang A, et al. (2011) Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet 43: 875-878.
21. Rebouissou S, Hérault A, Letouzé E, Neuzillet Y, Laplanche A, et al. (2012) CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma. J Pathol 227: 315-324.
22. Eymin B, Leduc C, Coll JL, Brambilla E, Gazzeri S, (2003) p14ARF induces G2 arrest and apoptosis independently of p53 leading to regression of tumours established in nude mice. Oncogene 22: 1822-1835.
23. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, et al. (2004) Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119: 847-60.
24. Camplejohn RS, Sodha N, Gilchrist R, Lomax ME, Duddy PM, et al. (2000) The value of rapid functional assays of germline p53 status in LFS and LFL families. Br J Cancer 82: 1145-1148.
25. Platz CE, Cohen MB, Jones MP, Olson DB, Lynch CF, (1996) Is microstaging of early invasive cancer of the urinary bladder possible or useful? Mod Pathol 9: 1035-1039.
26. Giedl J, Wild PJ, Stoehr R, Junker K, Boehm S, et al. (2006) Urothelial neoplasms in individuals younger than 20 years show very few genetic alterations and have a favourable clinical outcome. Verh Dtsch Ges Pathol 90: 253-263.
27. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. J Clin Epidemiol 62: e1-34.
28. van Oers JM, Lurkin I, van Exsel AJ, Nijsen Y, van Rhijn BW, et al. (2005) A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine. Clin Cancer Res 11: 7743-7748.
29. Bakkar AA, Quach V, Le Borgne A, Toublanc M, Henin D, et al. (2005) Sensitive allele-specific PCR assay able to detect FGFR3 mutations in tumors and urine from patients with urothelial cell carcinoma of the bladder. Clin Chem 51: 1555-15557.
30. Ishioka C, Frebourg T, Yan YX, Vidal M, Friend SH, et al. (1993) Screening patients for heterozygous p53 mutations using a functional assay in yeast. Nat Gene 5: 124-129.
31. Flaman JM, Frebourg T, Moreau V, Charbonnier F, Martin C, et al. (1995) A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci USA 92: 3963-3967.
32. van Rhijn BW, van der Kwast TH, Vis AN, Kirkels WJ, Boevé ER, et al. (2004) FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res 64: 1911-1914.
33. Millán-Rodríguez F, Chéchile-Toniolo G, Salvador-Bayarri J, Palou J, Vicente-Rodríguez J, (2000) Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 163: 73-78.
34. Reuter VE, (1999) Bladder. Risk and prognostic factors-a pathologist's perspective. Urol Clin North Am 26: 481-492.